2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Pediatric, Young Adult, Animal Model
PAPER

3225 Functional CRISPR screening identified genetic changes in TET2-deficient/RHOAG17V human CD4+ T-cells that cooperatively drive TFH lymphomagenesis

Anurag Kumar, PhD, Xuxiang Liu, PhD2, Jibin Zhang, PhD3, Alyssa Bouska, PhD4, Qi Wei, MD5, Abdul Rouf Mir, PhD6, Javeed Iqbal, PhD7, Wing C Chan, MD8
1 UNMC, Omaha, Nebraska, United States
2 UNMC, Omaha, Nebraska, United States
3 National Medical center City of hope, Duarte, California, United States
4 UNMC, Omaha, Nebraska, United States
5 Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China
6 UNMC, Omaha, Nebraska, United States
7 UNMC, Omaha, Nebraska, United States
8 National Medical center City of hope, Duarte, California, United States

Introduction:

            T-follicular helper cell lymphoma, particularly angioimmunoblastic T-cell lymphoma (TFHL-AI), is frequently characterized by the co-occurrence of TET2 loss-of-function mutations and the RHOAG17V hotspot mutation. Genome sequencing studies have identified recurrent TET2 and RHOAG17V mutations in up to approximately ~65% of AITL cases. We aimed to identify additional genetic vulnerabilities and cooperative interactions associated with RHOAG17V and TET2-deficient lesions to better understand the molecular basis of TFHL-AI development.

 

Methods:

            Primary human CD4⁺ T cells were isolated from peripheral blood mononuclear cells (PBMCs) and engineered using CRISPR-Cas9 to generate TET2-/-; RHOAG17V cells for cellular and functional studies. A pooled CRISPR-Cas9 loss-of-function screen was performed in these cells to identify potential genetic cooperations. Screen hits were evaluated by in vitro growth assays using flow cytometry and validated in vivo through transplantation into NSG mice to assess proliferative and pathogenic potentials.

 

Results:

        TET2-/-;RHOAG17V CD4+ T cells showed marked change in growth kinetics and proliferation relative to single edited cells including TET2-/- or RHOAG17V. The double mutant edited cells showed upregulated TFH associated markers, including ICOS, CCR7, PD‑1, and BCL6, relative to single gene edited cells. TET2-/-; RHOAG17V cells exhibited selective hyperactivation of AKT and NF‑κB signaling with reduced Foxo1(Ser256) phosphorylation upon TCR (CD3/28) co-stimulation.

   CRISPR screen against a panel of genes recurrently altered in PTCL or important in T-cell biology revealed distinct patterns of positively and negatively selected genes over time. Gene enrichment analyses identified PLCG1, HEYL, and MEF2A among the most significantly positively selected hits, with these genes consistently ranking among the top candidates across all time points. Enrichment of sgRNAs targeting these genes suggests that loss of PLCG1, HEYL, or MEF2A provides a selective growth and/or survival advantage in the context of TET2 loss and RHOAG17V expression, highlighting potential genetic cooperation regulating fitness of these cells. Targeted validation using individual sgRNAs confirmed these findings: two out of three sgRNAs for PLCG1 and HEYL, and one for MEF2A, consistently increased the proportion of RFP⁺ (sgRNA‑expressing) cells over time and validated these genes as cooperative lesions that potentiate the proliferative fitness of TET2‑/‑; RHOAG17V primary human CD4⁺ T cells in- vitro.

            To evaluate the in‑vivo consequences of these cooperative perturbations, we engrafted engineered TET2‑/‑; RHOAG17V CD4⁺ T cells carrying individual knockouts of PLCG1, HEYL, or MEF2A into NSG mice. All three modified populations successfully engrafted and expanded, with progressive increases in circulating human CD4⁺ T cells detected at days 35 and 55 post‑transplant. By day 55, knockout of PLCG1 yielded a 35.7‑fold expansion relative to controls TET2-/-; RHOAG17V only, whereas HEYL and MEF2A knockouts produced 22.5‑fold and 8.2‑fold increases, respectively. These results demonstrate that disruption of PLCG1, HEYL, or MEF2A markedly enhances the in‑vivo proliferative capacity of TET2‑/‑; RHOAG17V human CD4⁺ T cells.

 

Discussion:  

Our findings demonstrate that RHOAG17V alone in primary human CD4⁺ T cells produce minimal functional effects, whereas its combination with TET2 loss results in significant alterations in T-cell expansion and fitness. CRISPR screening identified PLCG1, HEYL, and MEF2A as cooperative genetic alterations that promote TET2 loss/RHOAG17V–driven T-cell expansion and enhance in vivo propagation. These findings reveal previously unrecognized regulatory nodes within signaling and transcriptional networks that may contribute to TFH lymphoma pathogenesis and provide potential targets for therapeutic intervention.

Anurag Kumar, PhD: No relevant conflicts of interest to declare.